Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Oncternal Therapeutics stock

Learn how to easily invest in Oncternal Therapeutics stock.

Oncternal Therapeutics Inc is a biotechnology business based in the US. Oncternal Therapeutics shares (ONCT) are listed on the NASDAQ and all prices are listed in US Dollars. Oncternal Therapeutics employs 26 staff and has a trailing 12-month revenue of around $3.6 million.

How to buy shares in Oncternal Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ONCT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Oncternal Therapeutics stock price (NASDAQ: ONCT)

Use our graph to track the performance of ONCT stocks over time.

Oncternal Therapeutics shares at a glance

Information last updated 2022-10-03.
Latest market close$0.97
52-week range$0.69 - $4.49
50-day moving average $1.06
200-day moving average $1.40
Wall St. target price$9.42
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.71

Buy Oncternal Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Oncternal Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oncternal Therapeutics price performance over time

Historical closes compared with the close of $0.97 from 2022-10-03

1 week (2022-09-28) 11.49%
1 month (2022-09-02) -11.82%
3 months (2022-07-05) -7.62%
6 months (2022-04-05) -31.21%
1 year (2021-10-05) -76.05%
2 years (2020-10-05) -45.81%
3 years (2019-10-04) 4.39
5 years (2017-10-05) 8.21

Oncternal Therapeutics financials

Revenue TTM $3.6 million
Gross profit TTM $-16,635,000
Return on assets TTM -25.95%
Return on equity TTM -44.58%
Profit margin 0%
Book value $1.42
Market capitalisation $47.4 million

TTM: trailing 12 months

Oncternal Therapeutics share dividends

We're not expecting Oncternal Therapeutics to pay a dividend over the next 12 months.

Have Oncternal Therapeutics's shares ever split?

Oncternal Therapeutics's shares were split on a 1:7 basis on 10 June 2019. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oncternal Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Oncternal Therapeutics shares which in turn could have impacted Oncternal Therapeutics's share price.

Oncternal Therapeutics share price volatility

Over the last 12 months, Oncternal Therapeutics's shares have ranged in value from as little as $0.69 up to $4.49. A popular way to gauge a stock's volatility is its "beta".

ONCT.US volatility(beta: 1.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncternal Therapeutics's is 1.3461. This would suggest that Oncternal Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Oncternal Therapeutics overview

Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc. ; and University of Tennessee Research Foundation.

Frequently asked questions

What percentage of Oncternal Therapeutics is owned by insiders or institutions?
Currently 9.164% of Oncternal Therapeutics shares are held by insiders and 22.911% by institutions.
How many people work for Oncternal Therapeutics?
Latest data suggests 26 work at Oncternal Therapeutics.
When does the fiscal year end for Oncternal Therapeutics?
Oncternal Therapeutics's fiscal year ends in December.
Where is Oncternal Therapeutics based?
Oncternal Therapeutics's address is: 12230 El Camino Real, San Diego, CA, United States, 92130
What is Oncternal Therapeutics's ISIN number?
Oncternal Therapeutics's international securities identification number is: US68236P1075
What is Oncternal Therapeutics's CUSIP number?
Oncternal Therapeutics's Committee on Uniform Securities Identification Procedures number is: 40052B108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site